25 May 2013
Keywords: boeh, ing, re-ly, trial, completes, enrollment, german
Article | 21 January 2008
German drug major Boehringer Ingelheim has completed enrollment in its landmark RE-LY trial, which is evaluating the long-term efficacy and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 January 2008
24 May 2013
© 2013 thepharmaletter.com